Edition:
United States

Neurocrine Biosciences Inc (NBIX.OQ)

NBIX.OQ on NASDAQ Stock Exchange Global Select Market

85.71USD
3:14pm EST
Change (% chg)

$1.13 (+1.34%)
Prev Close
$84.58
Open
$85.53
Day's High
$87.46
Day's Low
$83.91
Volume
240,624
Avg. Vol
356,995
52-wk High
$91.80
52-wk Low
$39.23

Chart for

About

Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-re... (more)

Overall

Beta: 0.31
Market Cap(Mil.): $7,484.74
Shares Outstanding(Mil.): 88.49
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 187.16 16.73
EPS (TTM): -- -- --
ROI: -- -0.71 35.60
ROE: -- -3.52 17.23

BRIEF-Neurocrine Will File NDA For Opicapone For Parkinson's Disease Based On Existing Pivotal Clinical Trial Data

* NEUROCRINE BIOSCIENCES WILL FILE NEW DRUG APPLICATION FOR OPICAPONE FOR PARKINSON'S DISEASE BASED ON EXISTING PIVOTAL CLINICAL TRIAL DATA

Feb 14 2018

BRIEF-Neurocrine Biosciences Reports Q4 Earnings Per Share $0.07

* NEUROCRINE BIOSCIENCES REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES INVESTOR UPDATE FOR 2018

Feb 13 2018

BRIEF-Neurocrine Biosciences Presents Long-Term Data Analyses From Open-Label Kinect 4 Phase III Study

* NEUROCRINE BIOSCIENCES PRESENTS LONG-TERM DATA ANALYSES FROM OPEN-LABEL KINECT 4 PHASE III STUDY DEMONSTRATING INGREZZA® IMPROVES TARDIVE DYSKINESIA SYMPTOMS Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Dec 04 2017

BRIEF-Neurocrine Biosciences appoints Matt Abernethy as CFO

* Neurocrine Biosciences appoints Matt Abernethy as chief financial officer

Nov 20 2017

BRIEF-Neurocrine Biosciences reports Q3 loss per share $0.13

* Q3 earnings per share view $-0.49 -- Thomson Reuters I/B/E/S

Nov 01 2017

BRIEF-Neurocrine initiates Phase IIb clinical study of Ingrezza

* Neurocrine initiates phase IIb clinical study of once-daily Ingrezza in children and adolescents with Tourette syndrome

Oct 25 2017

BRIEF-Neurocrine granted FDA orphan drug designation for Valbenazine

* Neurocrine granted FDA orphan drug designation for valbenazine for the treatment of pediatric patients with Tourette syndrome Source text for Eikon: Further company coverage:

Oct 23 2017

BRIEF-Neurocrine announces FDA approval of 80 mg Ingrezza

* Neurocrine announces FDA approval of 80 mg Ingrezza® (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD)

Oct 05 2017

BRIEF-Perceptive Advisors reports 5.3 pct passive stake in Neurocrine Biosciences

* Perceptive Advisors LLC reports 5.3 percent passive stake in Neurocrine Biosciences Inc as of September 6, 2017 - SEC filing‍​ Source: (http://bit.ly/2wOUVQY) Further company coverage:

Sep 08 2017

Earnings vs. Estimates